Terms: = Ovarian cancer AND RUNX1, PEBP2A2, 861, ENSG00000159216, Q01196, AML1, CBFA2, AMLCR1 AND Diagnosis
14 results:
1. Tumor-Stroma Proportion to Predict Chemoresistance in Patients With ovarian cancer.
Lou E; Clemente V; Grube M; Svedbom A; Nelson AC; Blome F; Staebler A; Kommoss S; Bazzaro M
JAMA Netw Open; 2024 Feb; 7(2):e240407. PubMed ID: 38411963
[TBL] [Abstract] [Full Text] [Related]
2. PROM1, CXCL8, runx1, NAV1 and TP73 genes as independent markers predictive of prognosis or response to treatment in two cohorts of high-grade serous ovarian cancer patients.
Dansonka-Mieszkowska A; Szafron LA; Kulesza M; Stachurska A; Leszczynski P; Tomczyk-Szatkowska A; Sobiczewski P; Parada J; Kulinczak M; Moes-Sosnowska J; Pienkowska-Grela B; Kupryjanczyk J; Chechlinska M; Szafron LM
PLoS One; 2022; 17(7):e0271539. PubMed ID: 35867729
[TBL] [Abstract] [Full Text] [Related]
3. Survival and Surgical Approach among Women with Advanced ovarian cancer Treated with Neoadjuvant Chemotherapy.
Persenaire C; Pyrzak A; Barber EL
J Minim Invasive Gynecol; 2022 Mar; 29(3):375-384. PubMed ID: 34648931
[TBL] [Abstract] [Full Text] [Related]
4. Chemotherapy After diagnosis of Malignant Bowel Obstruction is Associated with Superior Survival for Medicare Patients with Advanced Malignancy.
Bateni SB; Gingrich AA; Kirane AR; Sauder CAM; Gholami S; Bold RJ; Meyers FJ; Canter RJ
Ann Surg Oncol; 2021 Nov; 28(12):7555-7563. PubMed ID: 33829359
[TBL] [Abstract] [Full Text] [Related]
5. CircMUC16 promotes autophagy of epithelial ovarian cancer via interaction with ATG13 and miR-199a.
Gan X; Zhu H; Jiang X; Obiegbusi SC; Yong M; Long X; Hu J
Mol Cancer; 2020 Feb; 19(1):45. PubMed ID: 32111227
[TBL] [Abstract] [Full Text] [Related]
6. Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer.
Márton É; Lukács J; Penyige A; Janka E; Hegedüs L; Soltész B; Méhes G; Póka R; Nagy B; Szilágyi M
J Biotechnol; 2019 May; 297():58-65. PubMed ID: 30953675
[TBL] [Abstract] [Full Text] [Related]
7. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Vergote I; Coens C; Nankivell M; Kristensen GB; Parmar MKB; Ehlen T; Jayson GC; Johnson N; Swart AM; Verheijen R; McCluggage WG; Perren T; Panici PB; Kenter G; Casado A; Mendiola C; Stuart G; Reed NS; Kehoe S; ;
Lancet Oncol; 2018 Dec; 19(12):1680-1687. PubMed ID: 30413383
[TBL] [Abstract] [Full Text] [Related]
8. Overexpression of GPC6 and TMEM132D in Early Stage ovarian cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival.
Karapetsas A; Giannakakis A; Dangaj D; Lanitis E; Kynigopoulos S; Lambropoulou M; Tanyi JL; Galanis A; Kakolyris S; Trypsianis G; Coukos G; Sandaltzopoulos R
Biomed Res Int; 2015; 2015():712438. PubMed ID: 26448945
[TBL] [Abstract] [Full Text] [Related]
9. Frequent expression of napsin A in clear cell carcinoma of the endometrium: potential diagnostic utility.
Fadare O; Desouki MM; Gwin K; Hanley KZ; Jarboe EA; Liang SX; Quick CM; Zheng W; Parkash V; Hecht JL
Am J Surg Pathol; 2014 Feb; 38(2):189-96. PubMed ID: 24145649
[TBL] [Abstract] [Full Text] [Related]
10. Urinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer: a case--control study.
Macuks R; Baidekalna I; Donina S
Asian Pac J Cancer Prev; 2012; 13(9):4695-8. PubMed ID: 23167404
[TBL] [Abstract] [Full Text] [Related]
11. Circulating insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 levels and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort.
Schairer C; McCarty CA; Isaacs C; Sue LY; Pollak MN; Berg CD; Ziegler RG
Horm Cancer; 2010 Apr; 1(2):100-11. PubMed ID: 21761353
[TBL] [Abstract] [Full Text] [Related]
12. Ultrasound experience substantially impacts on diagnostic performance and confidence when adnexal masses are classified using pattern recognition.
Van Holsbeke C; Daemen A; Yazbek J; Holland TK; Bourne T; Mesens T; Lannoo L; Boes AS; Joos A; Van De Vijver A; Roggen N; de Moor B; de Jonge E; Testa AC; Valentin L; Jurkovic D; Timmerman D
Gynecol Obstet Invest; 2010; 69(3):160-8. PubMed ID: 20016188
[TBL] [Abstract] [Full Text] [Related]
13. High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of ovarian cancer.
Modan B; Gak E; Sade-Bruchim RB; Hirsh-Yechezkel G; Theodor L; Lubin F; Ben-Baruch G; Beller U; Fishman A; Dgani R; Menczer J; Papa M; Friedman E
JAMA; 1996 Dec; 276(22):1823-5. PubMed ID: 8946903
[TBL] [Abstract] [Full Text] [Related]
14. Relative frequency of primary ovarian neoplasms: a 10-year review.
Koonings PP; Campbell K; Mishell DR; Grimes DA
Obstet Gynecol; 1989 Dec; 74(6):921-6. PubMed ID: 2685680
[TBL] [Abstract] [Full Text] [Related]
